These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 32317559)

  • 1. Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study.
    van der Wouden CH; Böhringer S; Cecchin E; Cheung KC; Dávila-Fajardo CL; Deneer VHM; Dolžan V; Ingelman-Sundberg M; Jönsson S; Karlsson MO; Kriek M; Mitropoulou C; Patrinos GP; Pirmohamed M; Rial-Sebbag E; Samwald M; Schwab M; Steinberger D; Stingl J; Sunder-Plassmann G; Toffoli G; Turner RM; van Rhenen MH; van Zwet E; Swen JJ; Guchelaar HJ;
    Pharmacogenet Genomics; 2020 Aug; 30(6):131-144. PubMed ID: 32317559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.
    van der Wouden CH; Cambon-Thomsen A; Cecchin E; Cheung KC; Dávila-Fajardo CL; Deneer VH; Dolžan V; Ingelman-Sundberg M; Jönsson S; Karlsson MO; Kriek M; Mitropoulou C; Patrinos GP; Pirmohamed M; Samwald M; Schaeffeler E; Schwab M; Steinberger D; Stingl J; Sunder-Plassmann G; Toffoli G; Turner RM; van Rhenen MH; Swen JJ; Guchelaar HJ;
    Clin Pharmacol Ther; 2017 Mar; 101(3):341-358. PubMed ID: 28027596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Ubiquitous Pharmacogenomics consortium: making effective treatment optimization accessible to every European citizen.
    Manson LE; van der Wouden CH; Swen JJ; Guchelaar HJ
    Pharmacogenomics; 2017 Jul; 18(11):1041-1045. PubMed ID: 28685652
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical implementation of preemptive pharmacogenomics in psychiatry: Τhe "PREPARE" study.
    Tsermpini EE; Skokou M; Ferentinos P; Georgila E; Gourzis P; Assimakopoulos K; Patrinos GP;
    Psychiatriki; 2020; 31(4):341-351. PubMed ID: 33361064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The challenges of implementing pharmacogenomic testing in the clinic.
    Moyer AM; Caraballo PJ
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):567-577. PubMed ID: 28949250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of clinical impact of pharmacogenomics knowledge involved in CPIC guidelines on Chinese pediatric patients.
    Qin W; Du Z; Xiao J; Duan H; Shu Q; Li H
    Pharmacogenomics; 2020 Feb; 21(3):209-219. PubMed ID: 31967514
    [No Abstract]   [Full Text] [Related]  

  • 8. Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy.
    Bergmeijer TO; Vos GJ; Claassens DM; Janssen PW; Harms R; der Heide RV; Asselbergs FW; Ten Berg JM; Deneer VH
    Pharmacogenomics; 2018 May; 19(7):621-628. PubMed ID: 29701129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice.
    Cecchin E; Roncato R; Guchelaar HJ; Toffoli G;
    Curr Pharm Biotechnol; 2017; 18(3):204-209. PubMed ID: 28044932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice.
    Rosenman MB; Decker B; Levy KD; Holmes AM; Pratt VM; Eadon MT
    Value Health; 2017 Jan; 20(1):54-59. PubMed ID: 28212969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient insights on features of an effective pharmacogenomics patient portal.
    Truong TM; Lipschultz E; Schierer E; Danahey K; Ratain MJ; O'Donnell PH
    Pharmacogenet Genomics; 2020 Dec; 30(9):191-200. PubMed ID: 33017129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene-drug pairs across ambulatory care settings.
    Cicali EJ; Weitzel KW; Elsey AR; Orlando FA; Vinson M; Mosley S; Smith DM; Davis R; Drum L; Estores D; Franciosi JP; Hagen MG; Jerkins GJ; Mercado ES; Nainaparampil J; Padron A; Rosenberg EI; Wright A; Schmidt SO; Mathews CA; Cavallari LH; Johnson JA
    Genet Med; 2019 Oct; 21(10):2264-2274. PubMed ID: 30926959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimising Adverse Drug Reactions and Verifying Economic Legitimacy-Pharmacogenomics Implementation in Children (MARVEL- PIC): protocol for a national randomised controlled trial of pharmacogenomics implementation.
    Conyers R; Halman A; Moore C; Stenta T; Felmingham B; Collier L; Khatri D; Spelman T; Williams E; Dyas R; Kotecha RS; Jessop S; Mateos MK; Swen J; Elliott DA
    BMJ Open; 2024 May; 14(5):e085115. PubMed ID: 38760050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic testing for adverse drug reaction prevention: systematic review of economic evaluations and the appraisal of quality matters for clinical practice and implementation.
    Turongkaravee S; Jittikoon J; Rochanathimoke O; Boyd K; Wu O; Chaikledkaew U
    BMC Health Serv Res; 2021 Oct; 21(1):1042. PubMed ID: 34600523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
    Cecchin E; De Mattia E; Ecca F; Toffoli G
    Drug Resist Updat; 2018 Jul; 39():18-40. PubMed ID: 30075835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpreting and Implementing Clinical Pharmacogenetic Tests: Perspectives From Service Providers.
    Hachad H; Ramsey LB; Scott SA
    Clin Pharmacol Ther; 2019 Aug; 106(2):298-301. PubMed ID: 31162629
    [No Abstract]   [Full Text] [Related]  

  • 17. Recommendations for pharmacogenetic testing in clinical practice guidelines in the US.
    Hertz DL; Bousman CA; McLeod HL; Monte AA; Voora D; Orlando LA; Crutchley RD; Brown B; Teeple W; Rogers S; Patel JN
    Am J Health Syst Pharm; 2024 Aug; 81(16):672-683. PubMed ID: 38652504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomic knowledge representation, reasoning and genome-based clinical decision support based on OWL 2 DL ontologies.
    Samwald M; Miñarro Giménez JA; Boyce RD; Freimuth RR; Adlassnig KP; Dumontier M
    BMC Med Inform Decis Mak; 2015 Feb; 15():12. PubMed ID: 25880555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice.
    Chatelin J; Stathopoulou MG; Arguinano AA; Xie T; Visvikis-Siest S
    Curr Pharm Biotechnol; 2017; 18(3):231-241. PubMed ID: 28117005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of high-impact gene-drug pairs for pharmacogenetic testing in Alberta, Canada.
    Fan M; Yarema MC; Box A; Hume S; Aitchison KJ; Bousman CA
    Pharmacogenet Genomics; 2021 Feb; 31(2):29-39. PubMed ID: 32826605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.